Lay summary
Cancer drug therapy must find a balance between the inhibition of tumour growth and the unavoidable side effects of treatment. This balance usually involves compromise, leading to sub-optimal tumour inhibition and ‘tolerable’ but still debilitating toxicity to the patient.
One means to avoid this compromise is tissue-specific targeting. For most tissues, this is very difficult or impractical. However, the accessibility and unique physiology of the stomach provides a unique opportunity to deliver high-dose cancer chemotherapy to this organ without dose-limiting side effects. We propose to develop a drug delivery system for the better treatment of localised stomach cancer and its precursor lesions.